PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
34.57%
Cash & equivalents yoy growth below half of AXSM's 345.02%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
68.63%
Short-term investments yoy growth below half of AXSM's -100.00%. Michael Burry might see potential liquidity risk. Investigate alternative capital uses or constraints.
34.59%
Below half of AXSM's 145.02%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.58%
Below half of AXSM's 154.69%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-15.03%
Both AXSM and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.19%
Below half of AXSM's 107.94%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Higher Total Assets Growth compared to AXSM's zero value, indicating better performance.
-18.99%
Higher Accounts Payable Growth compared to AXSM's zero value, indicating worse performance.
-51.38%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-91.88%
Both AXSM and the company show zero Deferred Revenue (Current) Growth.
-10.37%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
-15.50%
Higher Total Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.50%
Higher Total Liabilities Growth compared to AXSM's zero value, indicating worse performance.
13.39%
Higher Common Stock (Book Value) Growth compared to AXSM's zero value, indicating worse performance.
-7.92%
Both AXSM and the company show zero Retained Earnings Growth.
-32.48%
Less than half of AXSM's 100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
41.56%
Below half AXSM's -125.19%. Michael Burry sees potential underperformance in building shareholder capital.
31.29%
Below half AXSM's 314.67%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
68.63%
Below half AXSM's -100.00%. Michael Burry suspects major underinvestment or forced divestment.
-51.38%
Higher Total Debt Growth compared to AXSM's zero value, indicating worse performance.
-35.43%
Less than half of AXSM's 71.69%. David Dodd sees better deleveraging or stronger cash buildup than competitor.